We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Hold on to OPKO Health (OPK) Stock For Now
Read MoreHide Full Article
OPKO Health, Inc. (OPK - Free Report) is well poised for growth in the coming quarters, backed by its potential in Rayaldee. A robust first-quarter 2022 performance, along with a few strategic agreements, is expected to contribute further. Stiff competition and concerns regarding overdependence on Rayaldee persist.
Over the past year, this Zacks Rank #3 (Hold) stock has lost 29.4% compared with 24% fall of the industry and 16.8% decline of the S&P 500.
The renowned multinational biopharmaceutical and diagnostics company has a market capitalization of $1.80 billion. It projects 27.3% growth for 2023 and expects to maintain its strong performance. OPKO Health’s earnings surpassed the Zacks Consensus Estimate in one of the trailing four quarters, missed the same in two and broke even in the other, with the average earnings surprise being -4.2%.
Image Source: Zacks Investment Research
Let’s delve deeper.
Potential in Rayaldee: We are upbeat about OPKO Health’s Rayaldee business. In February, OPKO Health announced that Vifor Fresenius Medical Care Renal Pharma has initiated the commercial launch of RAYALDEE (extended-release calcifediol) in Germany, the first launch of RAYALDEE outside the United States.
In December 2021, OPKO Health announced preliminary top-line results from its Phase 2 trial with Rayaldee to treat mild-to-moderate COVID-19, which indicates that vitamin D repletion therapy can accelerate recovery from COVID-19.
Strategic Agreements: OPKO Health has entered into a slew of agreements over the past few months, raising our optimism. In May, it announced the acquisition of privately held biotechnology company, ModeX Therapeutics, Inc.
Also in May, OPKO Health’s wholly owned subsidiary, GeneDx, LLC, was acquired by artificial intelligence-driven genomic and clinical data intelligence platform company, Sema4. The buyout deal was announced in January.
Strong Q1 Results: OPKO Health’s solid first-quarter 2022 results buoy our optimism. Uptick in year-over-year Pharmaceuticals revenues is encouraging. Improvements in genomic test reimbursement and an increase in clinical and genomic test volumes are promising. OPKO Health’s strength in its women's health and oncology businesses also augurs well. Robust adoption of the company’s digital health services and the newly-launched Scarlet platform also buoy our optimism.
Downsides
Stiff Competition: The pharmaceutical, diagnostic, and laboratory testing industries are highly competitive and require an ongoing, extensive search for technological innovation. Numerous companies, including major pharmaceutical companies, specialty pharmaceutical companies and specialized biotechnology companies, are engaged in the development, manufacture and marketing of pharmaceutical products that can be competitions for those that OPKO Health intends to commercialize itself and through its partners.
Overdependence on Rayaldee: OPKO Health’s Rayaldee is the company’s only pharmaceutical product approved for marketing in the United States. The company’s ability to generate revenues from product sales and achieve profitability is substantially dependent on its ability to effectively commercialize Rayaldee. Failure to successfully commercialize Rayaldee would have a material adverse effect on the company’s business, financial condition, cash flows and results of operations.
Estimate Trend
OPKO Health is witnessing a negative estimate revision trend for 2022. In the past 90 days, the Zacks Consensus Estimate for its earnings has widened from a loss of 9 cents per share to a loss of 22 cents.
The Zacks Consensus Estimate for the company’s second-quarter 2022 revenues is pegged at $319.5 million, suggesting a 27.8% fall from the year-ago quarter’s reported number.
Key Picks
Some better-ranked stocks in the broader medical space are AMN Healthcare Services, Inc. (AMN - Free Report) , Patterson Companies, Inc. (PDCO - Free Report) and McKesson Corporation (MCK - Free Report) .
AMN Healthcare, flaunting a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 1.1%. AMN’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average beat being 15.6%.
AMN Healthcare has gained 26.2% against the industry’s 32.9% fall in the past year.
Patterson Companies, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 9.6%. PDCO’s earnings surpassed estimates in all the trailing four quarters, the average beat being 16.5%.
Patterson Companies has gained 2.1% against the industry’s 11.3% fall over the past year.
McKesson, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 9.5%. MCK’s earnings surpassed estimates in three of the trailing four quarters, the average beat being 19.5%.
McKesson has gained 63.3% against the industry’s 11.3% fall over the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's Why You Should Hold on to OPKO Health (OPK) Stock For Now
OPKO Health, Inc. (OPK - Free Report) is well poised for growth in the coming quarters, backed by its potential in Rayaldee. A robust first-quarter 2022 performance, along with a few strategic agreements, is expected to contribute further. Stiff competition and concerns regarding overdependence on Rayaldee persist.
Over the past year, this Zacks Rank #3 (Hold) stock has lost 29.4% compared with 24% fall of the industry and 16.8% decline of the S&P 500.
The renowned multinational biopharmaceutical and diagnostics company has a market capitalization of $1.80 billion. It projects 27.3% growth for 2023 and expects to maintain its strong performance. OPKO Health’s earnings surpassed the Zacks Consensus Estimate in one of the trailing four quarters, missed the same in two and broke even in the other, with the average earnings surprise being -4.2%.
Image Source: Zacks Investment Research
Let’s delve deeper.
Potential in Rayaldee: We are upbeat about OPKO Health’s Rayaldee business. In February, OPKO Health announced that Vifor Fresenius Medical Care Renal Pharma has initiated the commercial launch of RAYALDEE (extended-release calcifediol) in Germany, the first launch of RAYALDEE outside the United States.
In December 2021, OPKO Health announced preliminary top-line results from its Phase 2 trial with Rayaldee to treat mild-to-moderate COVID-19, which indicates that vitamin D repletion therapy can accelerate recovery from COVID-19.
Strategic Agreements: OPKO Health has entered into a slew of agreements over the past few months, raising our optimism. In May, it announced the acquisition of privately held biotechnology company, ModeX Therapeutics, Inc.
Also in May, OPKO Health’s wholly owned subsidiary, GeneDx, LLC, was acquired by artificial intelligence-driven genomic and clinical data intelligence platform company, Sema4. The buyout deal was announced in January.
Strong Q1 Results: OPKO Health’s solid first-quarter 2022 results buoy our optimism. Uptick in year-over-year Pharmaceuticals revenues is encouraging. Improvements in genomic test reimbursement and an increase in clinical and genomic test volumes are promising. OPKO Health’s strength in its women's health and oncology businesses also augurs well. Robust adoption of the company’s digital health services and the newly-launched Scarlet platform also buoy our optimism.
Downsides
Stiff Competition: The pharmaceutical, diagnostic, and laboratory testing industries are highly competitive and require an ongoing, extensive search for technological innovation. Numerous companies, including major pharmaceutical companies, specialty pharmaceutical companies and specialized biotechnology companies, are engaged in the development, manufacture and marketing of pharmaceutical products that can be competitions for those that OPKO Health intends to commercialize itself and through its partners.
Overdependence on Rayaldee: OPKO Health’s Rayaldee is the company’s only pharmaceutical product approved for marketing in the United States. The company’s ability to generate revenues from product sales and achieve profitability is substantially dependent on its ability to effectively commercialize Rayaldee. Failure to successfully commercialize Rayaldee would have a material adverse effect on the company’s business, financial condition, cash flows and results of operations.
Estimate Trend
OPKO Health is witnessing a negative estimate revision trend for 2022. In the past 90 days, the Zacks Consensus Estimate for its earnings has widened from a loss of 9 cents per share to a loss of 22 cents.
The Zacks Consensus Estimate for the company’s second-quarter 2022 revenues is pegged at $319.5 million, suggesting a 27.8% fall from the year-ago quarter’s reported number.
Key Picks
Some better-ranked stocks in the broader medical space are AMN Healthcare Services, Inc. (AMN - Free Report) , Patterson Companies, Inc. (PDCO - Free Report) and McKesson Corporation (MCK - Free Report) .
AMN Healthcare, flaunting a Zacks Rank #1 (Strong Buy) at present, has an estimated long-term growth rate of 1.1%. AMN’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average beat being 15.6%.
You can see the complete list of today’s Zacks #1 Rank stocks here.
AMN Healthcare has gained 26.2% against the industry’s 32.9% fall in the past year.
Patterson Companies, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 9.6%. PDCO’s earnings surpassed estimates in all the trailing four quarters, the average beat being 16.5%.
Patterson Companies has gained 2.1% against the industry’s 11.3% fall over the past year.
McKesson, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 9.5%. MCK’s earnings surpassed estimates in three of the trailing four quarters, the average beat being 19.5%.
McKesson has gained 63.3% against the industry’s 11.3% fall over the past year.